Brevan Howard Capital Management’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.21M Sell
32,813
-16,429
-33% -$1.09M 0.02% 676
2026
Q1
$3.09M Sell
49,242
-2,266
-4% -$158K 0.03% 401
2025
Q4
$3.42M Buy
51,508
+24,977
+94% +$1.61M 0.04% 321
2025
Q3
$1.79M Buy
26,531
+21,592
+437% +$1.71M 0.01% 615
2025
Q2
$431K Buy
+4,939
New +$387K ﹤0.01% 1418
2025
Q1
– Sell
-3,350
Closed -$261K – 1230
2024
Q4
$261K Buy
+3,350
New +$248K ﹤0.01% 823
2024
Q1
– Sell
-12,565
Closed -$1.56M – 1085
2023
Q4
$1.56M Buy
12,565
+9,618
+326% +$983K 0.02% 154
2023
Q3
$275K Buy
+2,947
New +$332K ﹤0.01% 262

Other funds holding DXCM

Brevan Howard Capital Management's DXCM Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its DexCom (DXCM) stake by 33% in Q2 2026, selling an estimated $1.09M and leaving 32,813 shares worth $2.21M. The position accounts for 0.02% of the portfolio, ranked #676.

Brevan Howard Capital Management first reported a position in DXCM in Q3 2023 and has held it in 8 quarters since. The position peaked at $3.42M in Q4 2025. 976 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Brevan Howard Capital Management held 32,813 shares of DexCom worth $2.21M as of Q2 2026.
  • Brevan Howard Capital Management sold 16,429 DexCom shares in Q2 2026, an estimated $1.09M.
  • DexCom made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #676 holding.
  • Brevan Howard Capital Management first reported a position in DexCom in Q3 2023 and has held it in 8 quarters since.
  • Brevan Howard Capital Management's DexCom position peaked at $3.42M in Q4 2025.
  • 976 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.